$RGEN 8-K SEC Filings

Repligen Corporation41 Seyon StreetBuilding #1, Suite 100Waltham, Massachusetts 02453

WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisit...

On September 10, 2026, Karen A. Dawes notified Repligen Corporation (“Repligen”) that she will be retiring from the Repligen Board of Directors (the “Board”) after over twenty years of distinguished service to Repligen, effective as of S...

As previously disclosed, on July 21, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bravo Merger Sub I, Inc., a Delaware corporation and wholly ...